Chengdu Maxvax Biotechnology
PrivateLast Round
Series D
Extension
Dec 25, 2025
Total Funding Raised
$359.84M
Company Overview
Chengdu Maxvax Biotechnology is a biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of innovative vaccines and novel adjuvants.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Chengdu Maxvax Biotechnology Comparables
Compare Chengdu Maxvax Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WestVac Biopharma Co., Ltd. | 81% | |
| Abogen Biosciences | 81% | |
| RecBio | 78% |
Chengdu Maxvax Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | Dec 25, 2025 | ||||
| Series D | Oct 31, 2025 | ||||
| Series C Extension | Jun 11, 2024 | ||||
| Series C | Feb 6, 2024 | ||||
| Series B Extension | Dec 7, 2022 | ||||
Series B | Jul 20, 2022 |
Chengdu Maxvax Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GF Qianhe Investment | Series B Extension |
| IDG Capital | Series D, Series C Extension |
| Korea Investment Partners | Pre Seed |
| Hillhouse Investment | Series B, Series A |
| Gortune Investment | Series B Extension |
| Korea Investment Partners | Series A |
| Guohai Innovation Capital Investment Management | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 11, 2024
$41.4M round led by IDG Capital
- Dec 7, 2022
$43M round led by GF Qianhe Investment.
Chengdu Maxvax Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Chengdu Maxvax Biotechnology's valuation, stock price, and market status.
Is Chengdu Maxvax Biotechnology a public or private company?
Chengdu Maxvax Biotechnology is a private company.
What is the current stock price of Chengdu Maxvax Biotechnology?
Chengdu Maxvax Biotechnology is a private company, so its shares have no public market price. Caplight tracks Chengdu Maxvax Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Chengdu Maxvax Biotechnology worth (valuation)?
Valuation information for Chengdu Maxvax Biotechnology is not publicly available.
Can I buy Chengdu Maxvax Biotechnology stock?
Chengdu Maxvax Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Chengdu Maxvax Biotechnology's last funding round?
Chengdu Maxvax Biotechnology's most recent funding round was Series D Extension on December 25, 2025.
Who are the main investors in Chengdu Maxvax Biotechnology?
Key investors in Chengdu Maxvax Biotechnology include GF Qianhe Investment, IDG Capital, Hillhouse Investment, China Life Private Equity Investment Co., Ltd., Shenzhen Capital Group.
Will Chengdu Maxvax Biotechnology IPO soon?
No public IPO plans have been announced for Chengdu Maxvax Biotechnology.
How can I track Chengdu Maxvax Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Chengdu Maxvax Biotechnology's shares on secondary markets.